• Mylan to pay $5M up front in addition to $25M (according to 2018 deal)- contingent payments ~$100M- ~$225M milestones on the achievement of specified clinical and regulatory milestones and royalties on sales of the biosimilar in Mylan territories
• The amendment is made in the extension of time for Mylan to develop and commercialize biosimilar of BOTOX (onabotulinumtoxinA). Additionally- Mylan must inform Revance by Aprl’20- or 30 days before the date of to deliver from the date that the Company provides Mylan with certain deliverables
• BOTOX (onabotulinumtoxinA) is a neuromuscular agent- approved incontinence due to neurological conditions- prophylaxis of headache in patients with migraine- upper limb spasticity- cervical dystonia- and strabismus

Click here to read full press release/ article | Ref: Mylan | Image: Twitter